March 31, 2022 News by Steve Bryson, PhD Most Patients Adhere to Betaseron Therapy Over 1 Year, App Data Show Multiple sclerosis (MS) patients treated with Betaseron (interferon beta-1b) had over 90% treatment compliance — the percentage of doses administered — over one year, according to a study of data collected by the BETACONNECT autoinjector and the myBETAapp. After one year, the number of patients still using Betaseron…
October 9, 2017 News by Ashraf Malhas, PhD BETACONNECT Auto-injector Helps MS Patients Stick with Treatment, Study Reports Most multiple sclerosis patients who try Bayer’s BETACONNECT auto-injector stick with their treatment, a study reports. The electronic product may overcome the problem of many patients failing to stick to a therapy schedule because of what they consider hassles connected with injections. An auto-injector is one that patients can use…
June 5, 2017 News by Patricia Silva, PhD FDA Approves Two Bayer Products to Help MS Patients Stay on Top of Interferon Injections The U.S. Food and Drug Administration has approved a supplemental biologics license application for two Bayer products that help multiple sclerosis patients keep track of their injections of Betaseron (interferon beta-1b). The products are the myBETAapp and the Betaconnect Navigator software. A biologics license application is a request for permission to market…
December 15, 2016 News by Patricia Silva, PhD FDA Accepts Bayer’s Supplemental BLA for myBETAapp and BETACONNECT Navigator for MS Patients The U.S. Food and Drug Administration (FDA) has accepted Bayer’s filing of a supplemental biologics license application (sBLA) for two products designed to improve the lives of people with multiple sclerosis (MS): myBETAapp and the BETACONNECT Navigator. Bayer created the BETACONNECT system to increase patient treatment compliance and improve…
June 3, 2016 News by Inês Martins, PhD #CMSC16 – Interview with Bayer’s VP and General Manager on Betaconnect/Betaseron and Customized Therapy Global pharma Bayer Healthcare aims to improve human health by diagnosing, preventing, and treating a variety of diseases. The company currently provides products for general medicine, hematology, neurology, oncology, and women’s healthcare. In 1993, Bayer’s Betaseron (interferon beta-1b) became the first disease-modifying drug to be approved by the U.S. Food and Drug Administration (FDA) for…
September 29, 2015 News by Patricia Silva, PhD FDA Approves BETACONNECT Autoinjector for BETASERON Delivery Bayer HealthCare is pleased to announce the US Food and Drug Administration (FDA) has granted the approval of BETACONNECT, a first-of-its-kind electronic autoinjector indicated as a treatment for relapsing-remitting multiple sclerosis (RRMS). For now, the drug delivery device is only compatible with BETASERON® (interferon beta-1b), and will soon be available come early 2016. While…
April 27, 2015 News by Patricia Silva, PhD FDA Accepts Bayer’s BETACONNECT License Application for Relapsing-Remitting Multiple Sclerosis Bayer HealthCare recently announced that the U.S. Food and Drug Administration (FDA) has accepted the filing of a supplemental Biologics License Application (sBLA) for BETACONNECT for the treatment of relapsing-remitting multiple sclerosis (MS). BETACONNECT is a new drug delivery option for patients under Bayer’s BETASERON® (interferon beta-1b) therapy. MS is a…
